Compare Newmont Corporation (NEM) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Newmont Corporation vs Recursion Pharmaceuticals Inc — how do they compare? Newmont Corporation trades at $128.63 (market cap $133.91B), while Recursion Pharmaceuticals Inc trades at $3.22 (market cap $1.86B). The key difference: Newmont Corporation is far larger — about 72× Recursion Pharmaceuticals Inc's market cap, and Newmont Corporation pays a 0.82% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| NEM | RXRX | |
|---|---|---|
Market Cap | $133.91B | $1.86B |
Sector | Basic Materials | Health |
52-Week High | $135.14 | $6.79 |
52-Week Low | $78.32 | $2.84 |
Enterprise Value | $130.50B | $1.38B |
Dividend Yield | 0.82% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Newmont Corporation (NEM) trades at $127.09, down 0.78% on the day, with strong fundamental performance including a 31.25% net income margin in 2025 and consistent earnings beats. The stock shows bullish technical signals with moving averages supporting upside, while recent news highlights production challenges and institutional accumulation. Revenue growth is robust, projected to reach $25.8 billion in 2026.
Outlook remains positive due to high analyst buy ratings (75.68%) and a $133.29 consensus price target, though risks include operational pressures and gold price volatility. The company's liquidity and debt reduction support shareholder returns, including dividends.
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Newmont Corporation
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
